Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,607.98 91.71 0.63%
TOPIX 1,178.17 4.80 0.41%
HANG SENG 22,760.24 64.23 0.28%

Progenics Acquires Molecular Insight Pharmaceuticals to Expand Oncology-Focused Pipeline



Progenics Acquires Molecular Insight Pharmaceuticals to Expand
Oncology-Focused Pipeline

 — Gains Therapeutic and Diagnostic Compounds That Deepen Strategic Focus on
                                PSMA Target —

             — Adds Late-Stage Ultra-Orphan Oncology Candidate —

TARRYTOWN, N.Y., Jan. 22, 2013 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals,
Inc. (Nasdaq:PGNX) today announced that it has acquired Molecular Insight
Pharmaceuticals, Inc., a clinical-stage private biotechnology company with a
small molecule chemistry pipeline aimed at enhancing cancer treatment.

"This is a pivotal moment for Progenics as we advance our plan to become a
preeminent oncology company," said Mark R. Baker, chief executive officer of
Progenics. "Molecular Insight's innovative small molecule compounds are an
excellent complement to our internally developed oncology programs. This
acquisition broadens our oncology pipeline, adding late-stage opportunities
and targeting additional types of cancer while deepening our strategic focus
on the PSMA antigen, which shows great promise as an oncology target."

Nelson K. Stacks, Molecular Insight's chief executive officer, "We are pleased
to have made this agreement with Progenics. This puts our innovative compounds
in the hands of an experienced commercial drug developer."

"We are gratified that Progenics will further develop our compounds to address
unmet medical needs in important patient populations," said John W. Babich,
Ph.D., Molecular Insight's president and chief scientific officer. "It is
rewarding for Molecular Insight's team to see their important work have the
potential to directly benefit patients suffering from cancer."

Under the terms of the all-stock transaction, Progenics exchanged 4,566,210
shares of its common stock (8.9% of the total outstanding post-transaction
shares) for all of the outstanding shares of Molecular Insight, which will
become a wholly-owned subsidiary of Progenics. Molecular Insight has no debt.
Progenics may make additional milestone payments to the former owners of
Molecular Insight based on future commercial sales of the company's compounds.
No royalties are due to the former owners of Molecular Insight.

Key elements of Molecular Insight's pipeline of targeted radiotherapy and
molecular imaging compounds are:

Azedra™ radiotherapy for pheochromocytoma and potential additional indications

  * Compelling data in a phase 2 registrational trial for pheochromocytoma, an
    ultra-orphan adrenal tumor indication
  * Is in development under a Special Protocol Assessment with the U.S. Food
    and Drug Administration using a surrogate marker registrational endpoint
  * Potential for use in neuroblastoma and other neuroendicrine diseases

Trofex™ imaging agent with potential to alter clinical practice in treating
prostate cancer

  * Phase 2 study ongoing in metastatic prostate cancer
  * Highly sensitive and selective radioisotope small molecule targeting PSMA
    uses technetium-99m for metastatic and localized prostate cancer imaging
    and detection
  * Designed as an improved imaging agent that identifies cancer cells in soft
    tissue and bone, where current agents are insufficient

MIP-1466 small molecule therapeutic for metastatic prostate cancer and other
PSMA-expressing cancers

  * Targets the PSMA antigen with a radioactive payload
  * In preclinical development with evidence of dose-dependent enhanced tumor
    kill and prolonged survival in animal models of human prostate cancer
  * Investigator-initiated study in Germany of men with late-stage metastatic
    prostate cancer demonstrated tumor reduction for more than 14 days and a
    greater than 50% decrease in PSA levels in eight of 14 evaluable patients.

Robert J. Israel, M.D., Progenics' senior vice president of medical affairs
and clinical research said, "This is an exciting opportunity to enhance our
ability to help patients suffering from prostate cancer, and to add a
late-stage, ultra-orphan product candidate to our pipeline. In the coming
months, we will work toward integrating our companies and develop an optimal
path forward for key programs."

Conference Call and Webcast

Progenics will discuss its acquisition of Molecular Insight in a conference
call today at 8:00 a.m. EST. To participate, please dial (877) 250-8889
(domestic) or (720) 545-0001 (international) and reference conference ID
91616836. A live webcast will be available on the Events section of the
Progenics website, www.progenics.com, and a replay will be available on the
website for two weeks.

About Progenics

Progenics Pharmaceuticals, Inc. is discovering and developing innovative
medicines to treat disease, focusing on cancer and related conditions, with a
pipeline that includes product candidates in preclinical through late-stage
development. Progenics' first commercial product, Relistor® (methylnaltrexone
bromide) for opioid-induced constipation, is marketed and in further
development by Salix Pharmaceuticals, Ltd. for markets worldwide other than
Japan, where Ono Pharmaceutical Co., Ltd. holds an exclusive license for the
subcutaneous formulation. For additional information, please visit
www.progenics.com.

The Progenics Pharmaceuticals Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=9678

This press release may contain projections and other forward-looking
statements regarding future events. Such statements are predictions only, and
are subject to risks and uncertainties that could cause actual events or
results to differ materially. These risks and uncertainties include, among
others, the cost, timing and results of clinical trials and other development
activities; the unpredictability of the duration and results of regulatory
review of New Drug Applications and Investigational NDAs; market acceptance
for approved products; generic and other competition; the possible impairment
of, inability to obtain and costs of obtaining intellectual property rights;
and possible safety or efficacy concerns, general business, financial and
accounting matters, litigation and other risks. More information concerning
Progenics and such risks and uncertainties is available on its website, and in
its press releases and reports it files with the U.S. Securities and Exchange
Commission. Progenics is providing the information in this press release as of
its date and does not undertake any obligation to update or revise it, whether
as a result of new information, future events or circumstances or otherwise.

Additional information concerning Progenics and its business may be available
in press releases or other public announcements and public filings made after
this release.

(PGNX-G)

CONTACT: Amy Martini
         Corporate Affairs
         (914) 789-2816
         amartini@progenics.com

company logo
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement